Thinly traded nano cap Citius Pharmaceuticals (CTXR +7.1%) is up on a healthy 47x surge in volume in reaction to its license agreement with MD Anderson Cancer Center to develop and commercialize a product called “Mino-Wrap,” a gel-based wrap containing minocycline and rifampin designed to reduce post-operative infections associated with surgical implants.
Specifically, the product is aimed at reducing tissue expander (TE) infections following breast reconstructive surgery. A TE is a silicon implant that is placed in the mastectomy space and inflated with saline over a period of time to prepare the area for a permanent breast implant. The rate of TE-related infections is between 2.5 – 24%, depending on a range of factors such as the extent of the surgery and duration of postoperative drainage.
Mino-Wrap (CITI 101) is currently being evaluated in a Phase 3 study.
Minocycline is a tetracycline antibiotic used to treat severe acne. Rifampin is also an antibiotic, typically used to treat bacterial infections.